# Nephros Inc: financial statements, quarterly

NEPH · Nasdaq · CIK 1196298 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/neph.md) · [Financials](/companies/neph/financials.md) · [Filings](/companies/neph/filings.md) · [Insiders](/companies/neph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3,742](/filings/0001493152-24-045793.md) | [3,254 d](/filings/0001641172-25-000234.md) | [3,522](/filings/0001641172-25-010836.md) | [3,252](/filings/0001641172-25-022596.md) | [3,518](/filings/0001493152-25-021061.md) | [3,870 d](/filings/0001493152-26-009848.md) | [4,877](/filings/0001493152-26-021701.md) | [4,419](/filings/0001493152-26-036851.md) | [4,764](/filings/0001493152-25-021061.md) | [4,729 d](/filings/0001493152-26-009848.md) | [5,212](/filings/0001493152-26-021701.md) | [6,017](/filings/0001493152-26-036851.md) |
| Cost of revenue | $k | [1,548](/filings/0001493152-24-045793.md) | [1,233 d](/filings/0001641172-25-000234.md) | [1,335](/filings/0001641172-25-010836.md) | [1,340](/filings/0001641172-25-022596.md) | [1,369](/filings/0001493152-25-021061.md) | [1,395 d](/filings/0001493152-26-009848.md) | [1,723](/filings/0001493152-26-021701.md) | [1,624](/filings/0001493152-26-036851.md) | [1,849](/filings/0001493152-25-021061.md) | [1,968 d](/filings/0001493152-26-009848.md) | [2,219](/filings/0001493152-26-021701.md) | [1,991](/filings/0001493152-26-036851.md) |
| Gross profit | $k | [2,194](/filings/0001493152-24-045793.md) | [2,021 d](/filings/0001641172-25-000234.md) | [2,187](/filings/0001641172-25-010836.md) | [1,912](/filings/0001641172-25-022596.md) | [2,149](/filings/0001493152-25-021061.md) | [2,475 d](/filings/0001493152-26-009848.md) | [3,154](/filings/0001493152-26-021701.md) | [2,795](/filings/0001493152-26-036851.md) | [2,915](/filings/0001493152-25-021061.md) | [2,761 d](/filings/0001493152-26-009848.md) | [2,993](/filings/0001493152-26-021701.md) | [4,026](/filings/0001493152-26-036851.md) |
| Research and development | $k | [205](/filings/0001493152-24-045793.md) | [208 d](/filings/0001641172-25-000234.md) | [212](/filings/0001641172-25-010836.md) | [254](/filings/0001641172-25-022596.md) | [188](/filings/0001493152-25-021061.md) | [252 d](/filings/0001493152-26-009848.md) | [295](/filings/0001493152-26-021701.md) | [311](/filings/0001493152-26-036851.md) | [338](/filings/0001493152-25-021061.md) | [395 d](/filings/0001493152-26-009848.md) | [346](/filings/0001493152-26-021701.md) | [366](/filings/0001493152-26-036851.md) |
| Selling, general and administrative | $k | [2,137](/filings/0001493152-24-045793.md) | [2,411 d](/filings/0001641172-25-000234.md) | [2,142](/filings/0001641172-25-010836.md) | [1,941](/filings/0001641172-25-022596.md) | [1,721](/filings/0001493152-25-021061.md) | [1,872 d](/filings/0001493152-26-009848.md) | [2,254](/filings/0001493152-26-021701.md) | [2,201](/filings/0001493152-26-036851.md) | [2,229](/filings/0001493152-25-021061.md) | [2,316 d](/filings/0001493152-26-009848.md) | [2,521](/filings/0001493152-26-021701.md) | [2,418](/filings/0001493152-26-036851.md) |
| Operating income | $k | [(203)](/filings/0001493152-24-045793.md) | [(649) d](/filings/0001641172-25-000234.md) | [(200)](/filings/0001641172-25-010836.md) | [(317)](/filings/0001641172-25-022596.md) | [206](/filings/0001493152-25-021061.md) | [317 d](/filings/0001493152-26-009848.md) | [566](/filings/0001493152-26-021701.md) | [248](/filings/0001493152-26-036851.md) | [314](/filings/0001493152-25-021061.md) | [18.0 d](/filings/0001493152-26-009848.md) | [97.0](/filings/0001493152-26-021701.md) | [1,213](/filings/0001493152-26-036851.md) |
| Interest expense | $k | [0.0 d](/filings/0001493152-23-039890.md) | [1.0 d](/filings/0001493152-24-010107.md) | [1.0](/filings/0001493152-24-018483.md) | [0.0 d](/filings/0001641172-25-022596.md) | [0.0 d](/filings/0001493152-25-021061.md) | [0.0 d](/filings/0001493152-26-009848.md) | not reported | [1.0](/filings/0001493152-26-036851.md) | [0.0 d](/filings/0001493152-25-021061.md) | [0.0 d](/filings/0001493152-26-009848.md) | not reported | [1.0](/filings/0001493152-26-036851.md) |
| Income tax | $k | [0.0](/filings/0001493152-24-045793.md) | [0.0 d](/filings/0001493152-24-010107.md) | [0.0](/filings/0001493152-24-018483.md) | [0.0](/filings/0001493152-24-030745.md) | [0.0](/filings/0001493152-24-045793.md) | [15.0 d](/filings/0001493152-26-009848.md) | [0.0](/filings/0001493152-26-021701.md) | [9.0](/filings/0001493152-26-036851.md) | [3.0](/filings/0001493152-25-021061.md) | [0.0 d](/filings/0001493152-26-009848.md) | [0.0](/filings/0001493152-26-021701.md) | [13.0](/filings/0001493152-26-036851.md) |
| Net income | $k | [(182)](/filings/0001493152-24-045793.md) | [(654) d](/filings/0001641172-25-000234.md) | [(169)](/filings/0001493152-25-021061.md) | [(289)](/filings/0001493152-25-021061.md) | [183](/filings/0001493152-25-021061.md) | [349 d](/filings/0001493152-26-009848.md) | [558](/filings/0001493152-26-036851.md) | [237](/filings/0001493152-26-036851.md) | [337](/filings/0001493152-25-021061.md) | [62.0 d](/filings/0001493152-26-009848.md) | [140](/filings/0001493152-26-036851.md) | [1,197](/filings/0001493152-26-036851.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001493152-24-045793.md) | not reported | [(0.02)](/filings/0001641172-25-010836.md) | [(0.03)](/filings/0001641172-25-022596.md) | [0.02](/filings/0001493152-25-021061.md) | not reported | [0.05](/filings/0001493152-26-021701.md) | [0.02](/filings/0001493152-26-036851.md) | [0.03](/filings/0001493152-25-021061.md) | not reported | [0.01](/filings/0001493152-26-021701.md) | [0.11](/filings/0001493152-26-036851.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001493152-24-045793.md) | not reported | [(0.02)](/filings/0001641172-25-010836.md) | [(0.03)](/filings/0001641172-25-022596.md) | [0.02](/filings/0001493152-25-021061.md) | not reported | [0.05](/filings/0001493152-26-021701.md) | [0.02](/filings/0001493152-26-036851.md) | [0.03](/filings/0001493152-25-021061.md) | not reported | [0.01](/filings/0001493152-26-021701.md) | [0.11](/filings/0001493152-26-036851.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.6](/filings/0001493152-23-039890.md) | [4.3](/filings/0001641172-25-000234.md) | [3.6](/filings/0001493152-24-018483.md) | [3.1](/filings/0001493152-24-030745.md) | [2.5](/filings/0001493152-24-045793.md) | [3.8](/filings/0001493152-26-009848.md) | [4.1](/filings/0001641172-25-010836.md) | [5.1](/filings/0001641172-25-022596.md) | [5.2](/filings/0001493152-25-021061.md) | [5.4](/filings/0001493152-26-036851.md) | [4.0](/filings/0001493152-26-021701.md) | [4.7](/filings/0001493152-26-036851.md) |
| Current assets | $m | [8.5](/filings/0001493152-23-039890.md) | [8.4](/filings/0001641172-25-000234.md) | [8.1](/filings/0001493152-24-018483.md) | [7.9](/filings/0001493152-24-030745.md) | [7.4](/filings/0001493152-24-045793.md) | [8.3](/filings/0001493152-26-009848.md) | [9.0](/filings/0001641172-25-010836.md) | [9.6](/filings/0001641172-25-022596.md) | [10.7](/filings/0001493152-25-021061.md) | [11.2](/filings/0001493152-26-036851.md) | [11.5](/filings/0001493152-26-021701.md) | [13.6](/filings/0001493152-26-036851.md) |
| Total assets | $m | [10.9](/filings/0001493152-23-039890.md) | [11.9](/filings/0001641172-25-000234.md) | [11.4](/filings/0001493152-24-018483.md) | [11.1](/filings/0001493152-24-030745.md) | [10.4](/filings/0001493152-24-045793.md) | [11.2](/filings/0001493152-26-009848.md) | [11.8](/filings/0001641172-25-010836.md) | [12.2](/filings/0001641172-25-022596.md) | [13.2](/filings/0001493152-25-021061.md) | [13.6](/filings/0001493152-26-036851.md) | [13.8](/filings/0001493152-26-021701.md) | [15.8](/filings/0001493152-26-036851.md) |
| Current liabilities | $m | [1.8](/filings/0001493152-23-039890.md) | [2.1](/filings/0001641172-25-000234.md) | [1.9](/filings/0001493152-24-018483.md) | [2.0](/filings/0001493152-24-030745.md) | [1.1](/filings/0001493152-24-045793.md) | [1.6](/filings/0001493152-26-009848.md) | [1.5](/filings/0001641172-25-010836.md) | [1.8](/filings/0001641172-25-022596.md) | [2.5](/filings/0001493152-25-021061.md) | [2.8](/filings/0001493152-26-036851.md) | [2.5](/filings/0001493152-26-021701.md) | [3.3](/filings/0001493152-26-036851.md) |
| Total liabilities | $m | [2.3](/filings/0001493152-23-039890.md) | [3.5](/filings/0001641172-25-000234.md) | [3.2](/filings/0001493152-24-018483.md) | [3.2](/filings/0001493152-24-030745.md) | [2.2](/filings/0001493152-24-045793.md) | [2.6](/filings/0001493152-26-009848.md) | [2.5](/filings/0001641172-25-010836.md) | [2.6](/filings/0001641172-25-022596.md) | [3.2](/filings/0001493152-25-021061.md) | [3.4](/filings/0001493152-26-036851.md) | [3.1](/filings/0001493152-26-021701.md) | [3.8](/filings/0001493152-26-036851.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [8.6](/filings/0001493152-23-039890.md) | [8.4](/filings/0001493152-24-010107.md) | [8.2](/filings/0001493152-25-021061.md) | [7.9](/filings/0001493152-25-021061.md) | [8.2](/filings/0001493152-25-021061.md) | [8.6](/filings/0001493152-26-036851.md) | [9.3](/filings/0001493152-26-036851.md) | [9.6](/filings/0001493152-26-036851.md) | [10.0](/filings/0001493152-25-021061.md) | [10.2](/filings/0001493152-26-036851.md) | [10.7](/filings/0001493152-26-036851.md) | [12.0](/filings/0001493152-26-036851.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [562 d](/filings/0001493152-24-045793.md) | [(237) d](/filings/0001641172-25-000234.md) | [(672)](/filings/0001641172-25-010836.md) | [(501) d](/filings/0001641172-25-022596.md) | [(623) d](/filings/0001493152-25-021061.md) | [1,304 d](/filings/0001493152-26-009848.md) | [322](/filings/0001493152-26-021701.md) | [994 d](/filings/0001493152-26-036851.md) | [99.0 d](/filings/0001493152-25-021061.md) | [185 d](/filings/0001493152-26-036851.md) | [(1,671)](/filings/0001493152-26-021701.md) | [681 d](/filings/0001493152-26-036851.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-25-021061.md) | [0.0 d](/filings/0001493152-26-009848.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.3](/filings/0001493152-23-039890.md) | [10.3](/filings/0001493152-24-018483.md) | [10.3](/filings/0001493152-24-030745.md) | [10.5](/filings/0001493152-24-045793.md) | [10.5](/filings/0001641172-25-010836.md) | [10.5](/filings/0001641172-25-022596.md) | [10.6](/filings/0001493152-25-021061.md) | [10.6](/filings/0001493152-26-021701.md) | [10.8](/filings/0001493152-26-036851.md) | [11.0](/filings/0001493152-25-021061.md) | [11.0](/filings/0001493152-26-021701.md) | [11.1](/filings/0001493152-26-036851.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,860,120 at 2026-08-07, from the cover of the [10-Q filed 2026-08-10](/filings/0001493152-26-036851.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.